Preventing Packaging Errors from Disrupting a Multi-Country Clinical Trial
In complex clinical trials, packaging and labelling are often treated as necessary executional steps — but secondary. In reality, they are critical control points. Errors in packaging do not remain isolated. They can delay site activation, trigger rework, create regulatory exposure, and ultimately disrupt patient continuity. This case study explores how BAP Pharma supported a […]
Managing Multi-Country Labelling Complexity Without Delaying Trial Timelines
In multi-country clinical trials, labelling complexity increases rapidly. Different regulatory requirements, language variations, and country-specific interpretations all converge at a single point: the label. While often seen as an administrative step, labelling is in fact a compliance-critical component of trial delivery. Even minor inconsistencies can trigger delays, rework, or regulatory scrutiny.This case study explores how […]
Agile Approach to Comparator Sourcing
The Sponsor was initially unsure of their enrolment and subsequently experienced rapid patient enrolment, which led to the need for increased quantities of materials and an unexpected change in their packaging schedule. Their on-going forecast identified a risk in both the timely fulfilment and expedited delivery to meet their revised patient recruitment timelines.
BAP Pharma Granted Clinical Secondary Packaging and Labelling Licence
BAP Pharma are pleased to announce that the Government of Upper Bavaria (Regierung von Oberbayern) have granted a Clinical Secondary Packaging and Labelling licence, to our German facility. The new licence will enable BAP Pharma to offer bespoke Clinical Trial Secondary Packaging and Labelling services, to complement our award-winning Comparator Sourcing Division. Clinical Secondary Packaging […]